Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Jul 23, 2024 08:30AM
Biodexa Pharmaceuticals (BDRX) Prices $5 Million Registered Direct Offering and Concurrent Private Placement Jul 19, 2024 08:31AM
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Jul 19, 2024 08:30AM
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises May 22, 2024 08:30AM
Biodexa Pharmaceuticals (BDRX) Enters Exclusive License to eRapa Apr 26, 2024 08:31AM


Apr 26, 2024 08:30AM Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Apr 26, 2024 08:30AM Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Mar 1, 2024 08:00AM Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Dec 21, 2023 04:00PM Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Dec 19, 2023 08:42AM Biodexa Pharmaceuticals (BDRX) Prices $5.2M Share Offering at $2.20/sh
Dec 19, 2023 08:42AM Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
May 26, 2023 04:05PM Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
May 24, 2023 08:41AM Biodexa Pharmaceuticals (BDRX) Announces 22.14M Share Offering at $0.15/sh
May 24, 2023 08:40AM Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering